Treatment of Locally Advanced Parathyroid Carcinoma or Distant Metastases to Lung, Bone, or Liver
Parathyroid carcinoma frequently presents in a locally advanced state, and a significant proportion of patients develop distant metastases. When metastatic spread involves the lung, bone, or liver, first-line systemic therapy becomes the central management consideration.
Clinical Scenario
Parathyroid carcinoma is often locally advanced at presentation. Distant metastases can occur in the lung (40%), bone (30%), and liver (10%), placing these patients in a group requiring structured first-line systemic treatment planning.
First-Line Approach — Partial Overview
First-line systemic treatment in this setting draws on two broad therapeutic categories: antiangiogenic agents and alkylating agent-based chemotherapy regimens. The specific agents, combinations, and sequencing criteria are defined in the full evidence-based protocol.
Full regimen details, eligibility criteria, and selection guidance are available via the link below.
References
DOI: 10.1016/j.esmoop.2024.103664
PC is often locally advanced and distant metastases can occur in the lung (40%), bone (30%) and liver (10%).
First-line systemic treatment may involve antiangiogenic drugs [V, B] or alkylating agent-based ChT (dacarbazine, temozolomide or streptozocin combined with 5-FU or capecitabine) [V, C].
View source ↗